Premium
Gender effects of supplemental amino acids on non‐alcoholic fatty liver disease and chronic inflammation (1025.14)
Author(s) -
Belalcazar L. Maria,
Spratt Heidi,
Green Melanie,
Volpi Elena,
Hurren Nicholas,
Wolfe Robert,
Børsheim Elisabet
Publication year - 2014
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.28.1_supplement.1025.14
Subject(s) - medicine , steatosis , fatty liver , triglyceride , endocrinology , c reactive protein , liver disease , nonalcoholic fatty liver disease , inflammation , placebo , chronic liver disease , disease , cholesterol , cirrhosis , pathology , alternative medicine
Background: Non‐alcoholic liver disease increases with age. There is scant information on gender differences in relation to its behavior, health consequences and treatment response. Aims: 1). To examine gender effect on changes (Δ) in liver fat, body fat, and high‐sensitivity C‐reactive protein (hs‐CRP), a marker of subclinical inflammation and increased cardiovascular risk, in response to supplemental essential amino acids (sEAA); 2) To correlate Δ in liver and body fat with hs‐CRP Δ. Methods: 12 subjects (7 women) with impaired glucose tolerance, age 67 years, ingested 22 g of sEAA daily for 8 weeks, after a placebo run‐in. Participants did not change diet or physical activity. Liver fat (nuclear magnetic spectroscopy; n=7), body fat (DEXA) and hs‐CRP levels (ELISA) were measured. Results: Liver fat (0.403 to 0.209,intrahepatic triglyceride/Intralipid standard) and hs‐CRP (2.28 to 1.55 mg/L), but not body fat, decreased at 8 weeks from baseline. Analysis of variance showed a gender effect (p=0.047) for Δ in liver fat and hs‐CRP. Liver fat Δ, but not body fat Δ, was associated with hs‐CRP Δ in women (Spearman coefficients 0.63, p=0.067 overall; 0.9, p=0.037 in women; p=0.2 in men). Conclusion: There may be significant gender differences on the effects of sEAA on hepatic steatosis and hs‐CRP levels. Grant Funding Source : AG033761 , D34HP18956, UL1TR000071‐05, AG024832